Study:
A Phase 2a Multi-center, Randomized, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of T-817MAa in Patients With Mild to Moderate Alzheimer`s Disease
Rationale:
n/a
Purpose:
The primary objective of the study is to evaluate the efficacy of T-817MA in AD patients to
treat dementia. Efficacy will be cognitive function, as measured by the ADAS-cog cognitive
assessment.
The secondary objectives of the study are to evaluate the safety of T-817MA and the
activities of daily living (assessed with the ADCS-ADL) of AD patients taking T-817MA, and
to evaluate the efficacy of T-817MA in AD patients with an overall global assessment using
the ADCS-CGIC.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Alzheimer`s Disease |
Drug: T-817MA
Drug: Placebo |
Phase 2 |
Verified by
Toyama Chemical Co., Ltd.
December, 2012
Sponsored by: Toyama Chemical Co., Ltd.
Information provided by: Toyama Chemical Co., Ltd.
ClinicalTrials.gov identifier: NCT00663936
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Cleveland Clinic - Lou Ruvo Center for Brain Health
Las Vegas, Nevada 89106
United States
n/a